TY - JOUR
T1 - Eight novel mutations in SPG4 in a large sample of patients with hereditary spastic paraplegia
AU - Crippa, Francesca
AU - Panzeri, Chris
AU - Martinuzzi, Andrea
AU - Arnoldi, Alessia
AU - Redaelli, Francesca
AU - Tonelli, Alessandra
AU - Baschirotto, Cinzia
AU - Vazza, Giovanni
AU - Mostacciuolo, Maria Luisa
AU - Daga, Andrea
AU - Orso, Genny
AU - Profice, Paolo
AU - Trabacca, Antonio
AU - D'Angelo, Maria Grazia
AU - Comi, Giacomo Pietro
AU - Galbiati, Sara
AU - Lamperti, Costanza
AU - Bonato, Sara
AU - Pandolfo, Massimo
AU - Meola, Giovanni
AU - Musumeci, Olimpia
AU - Toscano, Antonio
AU - Trevisan, Carlo Pietro
AU - Bresolin, Nereo
AU - Bassi, Maria Teresa
PY - 2006/5
Y1 - 2006/5
N2 - Background: Hereditary spastic paraplegia (HSP) is a group of genetically heterogeneous disorders characterized by progressive spasticity of the lower limbs. Mutations in the SPG4 gene, which encodes spastin protein, are responsible for up to 45% of autosomal dominant cases. Objective: To search for disease-causing mutations in a large series of Italian patients with HSP. Design: Samples of DNA were analyzed by direct sequencing of all exons in SPG4. Samples from a subset of patients were also analyzed by direct sequencing of all exons in SPG3A, SPG6, SPG10, and SPG13. Setting: Molecular testing facility in Italy. Patients: Sixty unrelated Italian patients with pure (n=50) and complicated (n=10) HSP. Main Outcome Measures: Mutations in SPG4, SPG3A, SPG6, SPG10, and SPG13. Results:Weidentified 12 different mutations, 8 of which were novel, in 13 patients. No mutations of any of the other HSP genes tested were found in 15 patients with sporadic pure HSP who did not have mutations in the SPG4 gene. Conclusions: The overall rate of mutation in the SPG4 gene within our sample was 22%, rising to 26% when only patients with pure HSP were considered. The negative result obtained in 15 patients without mutations in SPG4 in whom 4 other genes were analyzed (SPG3A, SPG6, SPG10, and SPG13) indicate that these genes are not frequently mutated in sporadic pure HSP.
AB - Background: Hereditary spastic paraplegia (HSP) is a group of genetically heterogeneous disorders characterized by progressive spasticity of the lower limbs. Mutations in the SPG4 gene, which encodes spastin protein, are responsible for up to 45% of autosomal dominant cases. Objective: To search for disease-causing mutations in a large series of Italian patients with HSP. Design: Samples of DNA were analyzed by direct sequencing of all exons in SPG4. Samples from a subset of patients were also analyzed by direct sequencing of all exons in SPG3A, SPG6, SPG10, and SPG13. Setting: Molecular testing facility in Italy. Patients: Sixty unrelated Italian patients with pure (n=50) and complicated (n=10) HSP. Main Outcome Measures: Mutations in SPG4, SPG3A, SPG6, SPG10, and SPG13. Results:Weidentified 12 different mutations, 8 of which were novel, in 13 patients. No mutations of any of the other HSP genes tested were found in 15 patients with sporadic pure HSP who did not have mutations in the SPG4 gene. Conclusions: The overall rate of mutation in the SPG4 gene within our sample was 22%, rising to 26% when only patients with pure HSP were considered. The negative result obtained in 15 patients without mutations in SPG4 in whom 4 other genes were analyzed (SPG3A, SPG6, SPG10, and SPG13) indicate that these genes are not frequently mutated in sporadic pure HSP.
UR - http://www.scopus.com/inward/record.url?scp=33646420618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646420618&partnerID=8YFLogxK
M3 - Article
C2 - 16682546
AN - SCOPUS:33646420618
SN - 0003-9942
VL - 63
SP - 750
EP - 755
JO - Archives of Neurology
JF - Archives of Neurology
IS - 5
ER -